| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443640 | European Journal of Cancer | 2014 | 9 Pages |
Abstract
Bevacizumab was not found to be cost effective at its listed price, based on results from the MAX trial.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hannah E. Carter, Diana Zannino, R. John Simes, Deborah J. Schofield, Kirsten Howard, John R. Zalcberg, Timothy J. Price, Niall C. Tebbutt,